Currently, some guidelines suggest using apoB as a secondary intervention target of blood lipid management to reduce the residual risk of ASCVD in patients.[21,22] Therefore, apoB plays an essential role in the diagnosis and treatment of CVD. This evidence concerns the gene APOB and atherosclerosis.